Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14608016 | 0.89 | TAAR1 (0.53) | TAAR1IDO1AGXTMAOBSLC6A3 | |
| SCHEMBL7901300 | 0.85 | ENPP2 (0.46) | TAAR1ENPP2 | |
| SCHEMBL28648032 | 0.83 | TAAR1 (0.61) | TAAR1IDO1AGXTMAOBSLC6A3 | |
| SCHEMBL8209947 | 0.83 | TAAR1 (0.60) | TAAR1 | |
| SCHEMBL15734759 | 0.80 | TAAR1 (0.49) | TAAR1IDO1AGXTMAOBSLC6A3 | |
| SCHEMBL3371633 | 0.80 | TAAR1 (0.74) | TAAR1IDO1AGXTSLC6A3DRD2 | |
| SCHEMBL16450618 | 0.79 | TAAR1 (0.52) | TAAR1IDO1AGXTMAOBSLC6A3 | |
| SCHEMBL18970679 | 0.79 | TAAR1 (0.52) | TAAR1IDO1AGXTMAOBSLC6A3 | |
| SCHEMBL4797686 | 0.79 | IDO1 (0.64) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL30765138 | 0.79 | IDO1 (0.64) | TAAR1IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230021429-A1 | BASE-LABILE PROTECTING GROUPS FOR STEPWISE POLYMER SYNTHESIS | FANG SHIYUE (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | TAAR1 1183/4885IDO1 917/4885AGXT 3575/4885 |
| US-20230021429-A1 | BASE-LABILE PROTECTING GROUPS FOR STEPWISE POLYMER SYNTHESIS | PARG, PCNA, PARN | TAAR1 4275/4885IDO1 3944/4885AGXT 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.